Second chance: drug combo retested for tough colorectal cancer
NCT ID NCT07178717
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 30 times
Summary
This study tests whether giving a combination of two drugs (encorafenib and cetuximab) again can help people with a specific genetic type of advanced colorectal cancer (BRAF V600E mutation) who have already tried similar treatments. About 25 adults will receive the drugs in cycles until their cancer worsens or side effects become too severe. The main goal is to see how many patients are still cancer-free after 4 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, 08035, Spain
Contact Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.